M.D. Sass LLC Purchases 230,407 Shares of Henry Schein, Inc. $HSIC

M.D. Sass LLC raised its holdings in Henry Schein, Inc. (NASDAQ:HSIC) by 21.3% during the third quarter, HoldingsChannel reports. The firm owned 1,314,603 shares of the company’s stock after acquiring an additional 230,407 shares during the quarter. Henry Schein accounts for 7.1% of M.D. Sass LLC’s holdings, making the stock its largest position. M.D. Sass LLC’s holdings in Henry Schein were worth $87,250,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. CYBER HORNET ETFs LLC bought a new stake in Henry Schein during the 2nd quarter worth $25,000. MUFG Securities EMEA plc bought a new position in Henry Schein during the 2nd quarter worth approximately $27,000. ANTIPODES PARTNERS Ltd acquired a new position in Henry Schein in the second quarter valued at $43,000. Sentry Investment Management LLC lifted its stake in shares of Henry Schein by 132.1% in the 3rd quarter. Sentry Investment Management LLC now owns 905 shares of the company’s stock valued at $59,000 after purchasing an additional 515 shares during the period. Finally, Evelyn Partners Investment Management Services Ltd bought a new position in shares of Henry Schein during the 2nd quarter worth approximately $62,000. 96.62% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts have recently commented on HSIC shares. Weiss Ratings restated a “hold (c)” rating on shares of Henry Schein in a research note on Monday, December 29th. Mizuho set a $81.00 target price on shares of Henry Schein and gave the stock a “neutral” rating in a research note on Tuesday, January 20th. Wells Fargo & Company lifted their price target on Henry Schein from $70.00 to $76.00 and gave the stock an “equal weight” rating in a report on Wednesday, November 5th. Barclays started coverage on shares of Henry Schein in a research note on Monday, December 8th. They issued an “overweight” rating and a $86.00 target price on the stock. Finally, Morgan Stanley upped their price target on Henry Schein from $55.00 to $58.00 and gave the company an “underweight” rating in a research report on Wednesday, November 5th. Five equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $76.42.

Henry Schein Price Performance

NASDAQ:HSIC opened at $77.00 on Friday. The firm has a market capitalization of $9.06 billion, a price-to-earnings ratio of 24.37, a P/E/G ratio of 2.24 and a beta of 0.88. The company has a debt-to-equity ratio of 0.54, a quick ratio of 0.79 and a current ratio of 1.40. The stock has a fifty day moving average of $76.29 and a 200 day moving average of $70.94. Henry Schein, Inc. has a 52-week low of $60.56 and a 52-week high of $82.38.

Henry Schein (NASDAQ:HSIC) last announced its earnings results on Tuesday, November 4th. The company reported $1.38 earnings per share for the quarter, beating analysts’ consensus estimates of $1.27 by $0.11. Henry Schein had a net margin of 3.02% and a return on equity of 14.76%. The business had revenue of $3.34 billion for the quarter, compared to the consensus estimate of $3.28 billion. On average, research analysts expect that Henry Schein, Inc. will post 4.74 EPS for the current fiscal year.

About Henry Schein

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.